US FDA Director Proposes "Strategic Stockpiling of Infant Formula"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Kim Hyunjung] Robert Califf, Commissioner of the U.S. Food and Drug Administration (FDA), mentioned the need for strategic stockpiling of infant formula to respond to future shortages.

According to the Wall Street Journal (WSJ) on the 26th (local time), Commissioner Califf stated at a Senate Health, Education, Labor, and Pensions Committee hearing that recent government and private efforts are expected to stabilize the infant formula supply within two months. He emphasized, "The question is whether we need to maintain a government-led surplus (stockpile) of infant formula in the foreseeable future."

The United States has maintained strategic reserves for oil, antibiotics, and other items to prepare for shortages or emergencies. For medical supplies, the national stockpile is stably maintained and regularly monitored. Commissioner Califf did not comment on specific issues such as the shelf life of stockpiled infant formula.

At the committee hearing, criticism was also raised that the FDA did not adequately respond to whistleblowers regarding safety defects at infant formula factories. Senator Richard Burr pointed out, "The FDA’s catchphrase regarding infant formula is clearly 'complacency'." Commissioner Califf mentioned reform implementation, saying, "There are problems in the interaction system between the FDA and the industry."

Abbott, the manufacturer that triggered the recent infant formula shortage, voluntarily closed its factory in Sturgis, Michigan, in February after bacterial contamination and other violations were found in its products. The company expects to resume production at this factory around March 4.

Meanwhile, the Biden administration has invoked the Defense Production Act to expedite infant formula procurement, including easing import restrictions.